Current Issues of Pharmacy and Medical Sciences

Effect of combinational arginase and canavanine treatment on normal human peripheral blood lymphocytes in vitro

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 4, Pages 385-389

Oleh Chen1,2, Bohdanna Kavalets1,2, Marina Barska1, Lilianna Lyniv1,
Olena Vovk1, Natalia Sybirna2, Oleh Stasyk1

1 Department of Cell Signaling, Institute of Cell Biology of NAS of Ukraine, Lviv, Ukraine

2 Department of Biochemistry, Ivan Franko Lviv National University, Lviv, Ukraine


DOI: 10.12923/j.2084-980X/26.4/a.07

Abstract

Recombinant human arginase (rhARG)-based therapy to restrict arginine availability for malignant cells is a promising strategy to treat some cancers, including those of hematological origin. In the present study, we evaluated the action of combined rhARG treatment with canavanine (Cav) on proliferative potential and functional state of human peripheral blood lymphocytes (PBL) in vitro. We demonstrated that Cav in 0.1 mM concentration alone had no significant effect on proliferation and functional activity of normal activated PBL. Combined rhARG and Cav treatment inhibited proliferation and slightly promoted apoptosis in activated PBL but did not affect resting cells. However, the action of both drugs affected the ability of T cells for antigen activation. These results are important for further translational research on arginine-deprivation therapy. 

Keywords

arginase, canavanine, arginine deprivation, peripheral blood lymphocytes

References

  1. Bronte V., Zanovello P.: Regulation of immune responses by L – arginine metabolism. Nat. Rev. Immunol., 5, 641, 2005.
  2. Chen O.I. et al.: Effect of nitric oxide donor on viability of human leukemic cells upon arginine deprivation. Studia Biologica, 5, 17, 2011.
  3. Dean J.H., Hincks J.R., Remandet B.: Immunotoxicology assessment in the pharmaceutical industry. Toxicol. Lett., 102/103, 247, 1998.
  4. Denham S., Rowland I.J.: Inhibition of the reactive proliferation of lymphocytes by activated macrophages. The role of nitric oxide. Clin. Exp. Immunol., 87, 157, 1992.
  5. Engeland M., Nieland L.J., Ramaekers F.C.: Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry, 31, 1, 1998.
  6. Gregory S.H., Sagnimeni A.J., Wing E.J.: Arginine analogues suppress antigen-specific and -non-specific T lymphocyte proliferation. Cell Immunol., 153, 527, 1994.
  7. Green M.H., Ward J.F.: Enhancement of human tumor cell killing by L -canavanine in combination with g-radiation. Cancer Res., 43, 4180, 1983.
  8. Green L.C., David A.W., Clodowski J.: Analysis of nitrite, nitrite and ISN nitrate in biological fluids. Anal. Biochem., 126, 131, 1992.
  9. Jang M.H. et al.: Arginine antimetabolite L -canavanine induces apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-2 or Bcl-xLq. Biochem. Biophys. Res. Commun., 295, 283, 2002.
  10. Morimoto I. et al.: L-canavanine acts on suppressor-inducer T cells to regulate antibody synthesis: lymphocytes of systemic lupus erythematosus patients are specifically unresponsive to L-canavanine. Clin. Immunol. Immunopathol., 55, 97, 1990.
  11. Rodriguez P.C. et al.: Regulation of T cell receptor CD3 ξ chain expression by L -arginine. J. Biol. Chem., 277, 21123, 2002.
  12. Rodriguez P.C., Quiceno D.G., Ochoa A.C.: L -arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 109, 1568, 2007.
  13. Rosenthal G.A.: The biological effects and mode of action of L -canavanine, a structural analogue of L -arginine. Q. Rev. Biol., 52, 155, 1977.
  14. Swaffar D.S. et al.: Combination therapy with 5-fluorouracil and L -canavanine: in vitro and in vivo studies. Anticancer Drugs, 6, 586, 1995.
  15. Thomas D.A. et al.: Growth inhibition of a rat colon tumor by L -canavanine. Cancer Res., 46, 2898, 1986.
  16. Thomas D.A., Rosenthal G.A.: Toxicity and pharmacokinetics of the nonprotein amino acid L -canavanine in the rat. Toxicol. Appl. Pharmacol., 91, 395, 1987.
  17. Thomas Yau et al.: A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest. New Drugs, 31, 99, 2013.
  18. Vynnytska B. et al.: Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells. Anticancer Drugs, 22, 148, 2011.
  19. Worthen D.R. et al.: L -Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein substrate accumulation in cultured human tumor cell lines. Cancer Lett., 132, 229, 1998.
  20. Yang T-S et al.: A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients British Journal of Cancer, 103, 954, 2010.

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30